ArticleMolecular biology reports2026
Selective modulation of IL-6/JAK/STAT-related signaling under redox-shift conditions by luteolin.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLuteolin is a naturally occurring flavone known to modulate cellular redox balance and inflammatory signaling; however, its role in integrated redox-inflammatory responses remains incompletely defined. The present study investigated the effects of luteolin, alone and in combination with the selective JAK1 inhibitor upadacitinib, on oxidative stress parameters, inflammatory mediators, and JAK/STAT-related gene expression in human breast (MCF-7), colorectal (HT-29), and hepatocellular (HepG2) cancer cell lines, with L929 fibroblasts as a non-tumor comparator.
objectiveReal-time impedance analysis was used to establish cytotoxicity profiles and define submaximal, non-lethal exposure conditions. Under these conditions, total oxidant status (TOS), total antioxidant status (TAS), lipid peroxidation (MDA), catalase (CAT) activity, and glutathione (GSH) levels were assessed, together with interleukin-6 (IL-6) and interleukin-1β (IL-1β) secretion and transcriptional expression of JAK1, JAK2, JAK3, and STAT3.
methodsLuteolin exposure was associated with a consistent reduction in oxidative burden (decreased TOS and MDA) and enhancement of antioxidant capacity (increased TAS, CAT, and GSH) across cell lines, indicating a shift toward a more reduced intracellular state. These changes were accompanied by selective modulation of inflammatory signaling, characterized by a reduction in IL-6 secretion in a cell line-dependent manner, while IL-1β levels remained largely unchanged. Transcriptional downregulation of JAK/STAT pathway components was observed following luteolin exposure, with additional modulation in combination with upadacitinib.
resultsImportantly, these findings reflect transcriptional and biochemical alterations under basal, non-stimulated conditions and do not constitute direct evidence of functional pathway inhibition. Furthermore, the concentrations required to induce these effects exceed typical physiological levels, indicating that the observed responses should be interpreted within a mechanistic in vitro framework.
conclusionCollectively, the results demonstrate that luteolin induces a redox shift associated with selective modulation of IL-6-related signaling without broad cytokine suppression. These findings support the use of luteolin as a context-dependent redox modulator and a tool compound for investigating redox-inflammatory pathway interactions in vitro.
Indexed as
Identifiers
42397602What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.